

Curriculum Vitae du Responsable d'Équipe

Laurent Peyrin-Biroulet, MD, PhD, born in 1974, is Professor of Gastroenterology, head of the inflammatory bowel disease (IBD) group at Gastroenterology Department (CHU Nancy) and deputy director of INSERM UMRS 954.

Current academic positions : Professor Peyrin-Biroulet is the current President of the groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID) and current General Secretary of the European Crohn's & Colitis Organization (ECCO). He serves as Councillor to the Immunology, Microbiology and IBD section of the AGA Institute Council (2014-) and is the current Chair of the Clinical Trials Task Force at International Organization for the Study of Inflammatory Bowel Diseases (IOIBD).

Past-academic positions : Member of the UEGF Scientific Committee (2011-14). Past-President of the SciCom of the French association of IBD patients (AFA). Past-Chair of the IBD Committee of the French Society of Digestive Endoscopy (SFED). Past-director of Pôle BMS at Lorraine University (2012-14).

Invited conferences : 20 international invitations for lectures per year

Edition and peer review activity : Professor Peyrin-Biroulet is an associate editor of Digestive Liver Diseases, and a member of the editorial board of Alimentary Pharmacology & Therapeutics, Journal of Crohn's and colitis, Expert Rev Clin Immunol and Gut. He also serves as a reviewer for numerous international journals (NEJM, Lancet, Gastroenterology, Gut etc.) and he is a staff contributor of the Selected Summary section of Gastroenterology. He joined the editorial team of the Cochrane Inflammatory Bowel Diseases and Functional Bowel Disorders (IBD/FBD) Review Group in 2014.

Main scientific contributions : He was the coordinator for the development of the first Disability Index for IBD in close collaboration with WHO and of the treat to target (STRIDE) recommendations from the IOIBD. He proposed the first definitions of early Crohn's disease and of disease severity for IBD. He developed the first validated index for histological disease activity in ulcerative colitis. He also contributed to the ECCO workshops on mucosal healing and malignancies as a responsible for a working group. He participated in ECCO guidelines on imaging and Crohn's disease consensus and in the recent ECCO consensus on Crohn's disease. He is President of the ICARE project that will enroll 18,000 IBD patients across Europe followed for 3 years (2,100 patients were included since April 2016), a project endorsed by ECCO that received a grant of 6 millions euros.

Scientific production : 378 articles in PubMed over the past 10 years (Nat Genet, Lancet, J Clin Invest, Gastroenterology, PNAS, Gut etc.) and more than 200 non peer-reviewed articles. He was recently ranked as second best expert in the field of Crohn's disease worldwide by Expertscape and has an H-index of 44 in WOS.

List of 10 recent relevant publications on the topic :

1. Torres J, Mehandru S, Colombel JF, **Peyrin-Biroulet L**. Crohn's disease. Lancet (In Press).
2. Ungaro R, Mehandru S, Allen P, **Peyrin-Biroulet L**, Colombel JF. Ulcerative colitis. Lancet (In Press).
3. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S,

- Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, **Peyrin-Biroulet L**, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet*, 2011, PMID: 21297633.
4. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, **Peyrin-Biroulet L**. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. *Gut*, 2015, PMID: 26646934.
 5. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, **Peyrin-Biroulet L**. Development and validation of the Nancy histological index for UC. *Gut*, 2015, PMID: 26464414
 6. **Peyrin-Biroulet L**, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamailard M. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. *PNAS*, 2010, PMID: 20421464
 7. **Peyrin-Biroulet L**, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. *Gut*, 2014, PMID: 23974954
 8. Melhem H, Hansmannel F, Bressenot A, Battaglia-Hsu SF, Billioud V, Alberto JM, Gueant JL, **Peyrin-Biroulet L**. Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress. *Gut*, 2015, PMID: 25608526
 9. **Peyrin-Biroulet L**, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, Decourcelle C, Saudemont A, Tachon M, Béclin E, Odou MF, Neut C, Colombel JF, Desreumaux P. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. *Gut*, 2012, PMID: 21940721
 10. D'Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, **Peyrin-Biroulet L**, Fiocchi C, Danese S. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. *J Clin Invest*, 2014, PMID: 25105363